NovoCure TRIDENT Trial Misses Primary Endpoint in Glioblastoma

NovoCure announced topline results from its Phase 3 TRIDENT trial for newly diagnosed glioblastoma, which did not meet its primary endpoint of statistically significant improvement in overall survival. The Early Start Arm had a median overall survival of 17.7 months compared to 17.5 months in the Maintenance Start Arm. Despite the primary endpoint miss, TTFields therapy was well-tolerated with no new safety signals, and the results have been accepted for presentation at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting.